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Abstract 
Recent studies suggest that genetic and environmental factors do not account for all the 
schizophrenia risk and epigenetics also plays a role in disease susceptibility.  DNA 
methylation is a heritable epigenetic modification that can regulate gene expression.  
Genome-Wide DNA methylation analysis was performed on post-mortem human brain tissue 
from 24 patients with schizophrenia and 24 unaffected controls.  DNA methylation was 
assessed at over 485 000 CpG sites using the Illumina Infinium Human Methylation450 Bead 
Chip.  After adjusting for age and post-mortem interval (PMI), 4 641 probes corresponding to 
2 929 unique genes were found to be differentially methylated.  Of those genes, 1 291 were 
located in a CpG island and 817 were in a promoter region.  These include NOS1, AKT1, 
DTNBP1, DNMT1, PPP3CC and SOX10 which have previously been associated with 
schizophrenia.  More than 100 of these genes overlap with a previous DNA methylation 
study of peripheral blood from schizophrenia patients in which 27 000 CpG sites were 
analysed.  Unsupervised clustering analysis of the top 3 000 most variable probes revealed 
two distinct groups with significantly more people with schizophrenia in cluster one 
compared to controls (p = 1.74x10-4).  The first cluster was composed of 88% of patients with 
schizophrenia and only 12% controls while the second cluster was composed of 27% of 
patients with schizophrenia and 73% controls.  These results strongly suggest that differential 
DNA methylation is important in schizophrenia etiology and add support for the use of DNA 
methylation profiles as a future prognostic indicator of schizophrenia.   
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Introduction 
Despite schizophrenia being a debilitating disorder affecting 1% of the population there are 
no extant biomarkers to aid the clinician in identifying this disorder.  Studies predict the 
genetic risk to be up to 80% (1, 2) but despite strenuous research efforts the genes and 
polymorphisms found to be associated with schizophrenia account for very little of the 
genetic risk.  Environmental risk such as urbancity (3), migrant status (4), childhood 
maltreatment (5), prenatal infections (6), cannabis use (7) and maternal vitamin D deficiency 
(8) also contribute to schizophrenia susceptibility.  However not all individuals exposed to 
environmental risk develop schizophrenia (9).  This observation suggests that interaction 
between susceptibility genes and environmental factors may better account for schizophrenia.  
DNA methylation has been identified as a key mechanism for environmental regulation of 
gene expression (10).  DNA methylation is an epigenetic modification that is essential for 
normal human development via regulation of gene function.  DNA methylation results in the 
addition of a methyl group on the cytosine of CpG dinucleotides which can then be inherited 
through cell division.  These cytosine modifications can affect gene expression by altering the 
binding of transcription factors to promoter regions or changing mRNA processing.   
DNA methylation studies of brain and peripheral tissue have previously been reported for 
schizophrenia.  However to our knowledge, no study has published results from an Illumina 
Infinium HumanMethylation450 Beadchip in brain tissue of patients with schizophrenia.  
Studies to date have typically been performed in peripheral tissues and have been limited to 
the analysis of CpG islands in the promoter regions.  A recent  DNA methylation study 
analysed 27 578 CpG sites in peripheral blood cells from 18 patients with schizophrenia and 
15 normal controls (11).  This study revealed 603 CpG sites (representing 589 genes) that had 
significantly different DNA methylation levels between schizophrenia and controls.  Among 
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these genes were HTR1E, COMTD1 and SLC6A3 which have previously been found to be 
associated with schizophrenia.  An epigenetic study of monozygotic twins discordant for 
schizophrenia identified a number of loci differentially methylated in peripheral blood (12).  
Selected gene promoters have also been analysed for differential DNA methylation in brain 
tissue from small numbers of patients with schizophrenia.  Some of these genes include 
RELN (13, 14), COMT (15), SOX10 (16), HTR2A (17).  An earlier study of 12 000 CpG 
islands in frontal cortex of 35 schizophrenia and 35 controls revealed differential DNA 
methylation in genes associated with glutamatergic and GABAergic pathways (18).  Apart 
from the present study the only extant study using a 450 000 genome-wide methylation array 
was performed in leucocytes from patients with schizophrenia (19).   
DNA methylation analysis of schizophrenia has been more widely performed in peripheral 
tissue because it can be readily obtained from living patients.  The epigenetic profile differs 
in brain compared to peripheral tissue however some regions may have common patterns (20) 
which would make these regions ideal as potential biomarkers for schizophrenia.  Some of 
the genes found to be differentially methylated in peripheral tissue of schizophrenia patients 
include HTR1A (21), HTR2A (22), BDNF (23), GRM2 (24), GRM5 (24) and COMT (25, 26).   
Brain tissue from the Human Brain and Spinal Fluid Resource Centre, California was 
obtained in order to examine tissue involved in the etiology of schizophrenia.  We analysed 
this tissue in a genome-wide methylation study of schizophrenia.  We report significant 
differences in methylation status in brain tissue from schizophrenia patients compared to 
controls.  In addition, unsupervised clustering analysis revealed two distinct groups 
corresponding to schizophrenia and controls.  Results of future epigenetic studies hold great 
promise of a schizophrenia biomarker as well as treatment since epigenetic processes can be 
reversed.   
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Materials and Methods 
Samples 
Frontal cortex post-mortem brain tissue from individuals with DSM-IV diagnosed 
schizophrenia (n=24) and controls (n=24) was provided by the Human Brain and Spinal Fluid 
Resource Centre, California (courtesy of James Riehl).  Each sample consisted of a coronal 
section (7 mm thick) that had been quick frozen and a section of frontal cortex was dissected 
from each frozen section sample weighing (0.4-1.0 gram).  Demographic data including age, 
post-mortem interval (PMI) and gender are summarized in Table 1.  PMI in our study is 
defined as the time between death and when the brain section is quick frozen.  The mean 
(±SD) time between death and the tissue stored at 4°C was 4.48 ± 3.86.  All but two of the 
schizophrenia subjects were known to be receiving antipsychotic medication at time of death.  
Cause of death of five schizophrenia patients was suicide.  Extraction of DNA was performed 
at the UCLA Clinical Microarray Core Laboratory using the Roche MagNa Pure Compact.  
The quality and quantity of DNA was assessed using spectrophotometry and was found to be 
satisfactory for all samples.  Ethics approval for the project was obtained from the Human 
Research Ethics Committee of the Queensland University of Technology.   
Illumina Infinium HumanMethylation450 BeadChip 
DNA samples were sent to the Australian Genome Research Facility (AGRF) and stored at -
200C.  Quality checking of the samples was performed by Nanodrop Spectrophotometer and 
resolution on a 0.8% agarose gel.  Samples were bisulphite converted with Zymo EZ DNA 
Methylation kit.  GenomeStudio v2011.1 (Illumina) with Methylation module 1.9.0 software, 
with the default Illumina settings and Illumina HumanMethylation450_15017482_v.1.2 
manifest files was used in the methylation analysis.  The Infinium platform assays more than 
485 000 CpG sites, encompassing 99% of RefSeq genes.  It covers 96% of CpG islands with 
6 
 
multiple sites in the island, the shores (within 2 kb from CpG islands) and the shelves (>2 kb 
from CpG islands).  It also covers CpG sites outside of CpG islands and DNase 
hypersensitive sites as well as incorporating miRNA promoter regions.  All the Illumina 
quality controls were found to be in order which included sample-independent controls, 
sample dependent controls, staining controls, extension controls, target removal controls, 
hybridization controls, bisulphite conversion I and II controls, specificity controls, non-
polymorphic controls and negative controls.   
Data processing 
For methylation analysis IDAT files were loaded into the R (2.15) environment using the 
Bioconductor minfi package (1.4.0) (27).  The arrays were then background and control 
normalised using the minfi package.  Technical differences between Infinium I and Infinium 
II probes were removed using Subset-quantile Within Array Normalisation (SWAN), 
developed by Maksimovic et al. (28) and available in the minfi package. The methylation 
status for each probe was recorded as a beta value that ranged between 0 and 1, where values 
close to 1 represent high levels of methylation and where values close to 0 represent low 
levels of methylation.  
A detection p-value was calculated for all probes on all arrays. A p-value > 0.05 indicates that 
the data point is not significantly different from background measurements. Probes were 
removed from analysis if greater than 50% of the samples had a detection p-value greater 
than 0.05 (n=39).  
Next, probes that are designed for sequences on either the X (n=11 232) or Y (n=416) 
chromosome were removed. Finally, probes with SNPs present within 10-50 bp from query 
site (n=59 892), and within <10 bp from query site (n=36 535) were removed; with overlap 
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this totalled n=89 678 probes. Due to overlap in some of these conditions, n=100 345 probes 
were filtered leaving n=385 167 for analysis.  
Differential Methylation Detection 
In order to assess differences in methylation between groups, the original n=385 167 beta 
values were converted to M-values via the logit transformation as recommended by Du et al. 
(29). Differentially methylated probes were detected using the limma package (30). The 
limma procedure uses linear models to assess differential methylation whereby information is 
shared across probes (31). A major benefit of the limma procedure is it allows the inclusion 
of covariates (such as age) or other factors (such as PMI) in the specification of the linear 
model.  As such, we were able to adjust for age and PMI in the detection of differentially 
methylated probes by including age and autolysis covariates in the specification of the design 
matrix. Although most studies have found that methylation status is unaffected by PMI we 
decided to adjust for PMI as a confounder (32, 33).  Probes were considered to be 
differentially methylated if the resulting adjusted p-value was less than 0.05. The Benjamini 
Hochberg method (34) was used to adjust the p-values and ensure that the false discovery rate 
was less than 0.05. The corresponding gene list was derived from the gene annotations 
associated with the probes.  
Unsupervised Clustering 
For cluster analysis, the top 3 000 most variable probes were selected (based on the standard 
deviation of the beta value). A recursively partitioned mixture model (RPMM) was used to 
cluster the beta scores. RPMM is a model-based unsupervised clustering algorithm developed 
for measurements that lie between 0 and 1. This algorithm was implemented using the 
RPMM Bioconductor package (35). The implementation of RPMM was identical to Hinoue 
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et al. (36) who used a fuzzy clustering algorithm for initialisation and level-weighted version 
of BIC as a split criterion. 
In order to adjust for age and PMI, a series of linear models were fitted to the M-values (logit 
transformed beta values) using the function lmFit in the limma package. Coefficients for age 
and PMI, along with an intercept were estimated for each probe. Due to this model 
specification, the residuals of the linear model represent the methylation values adjusted for 
the effect of age and PMI. The residuals were then back-transformed and clustered using the 
RPMM method implemented for the unadjusted probes.  
To allow visualisation of the distance between samples and to further reinforce the RPMM 
clustering, multi-dimensional scaling (MDS) with a Euclidian distance metric was performed 
on both the adjusted M-values (before back transformation), and the adjusted beta values. 
The first two coordinates, along with the RPMM clusters were visualised in figure 2 and 
figure 2. 
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Results 
Differential Methylation 
Between the 24 controls and the 24 schizophrenia samples, a total of 19 582 probes were 
identified as differentially methylated (Supplementary Table 1). Approximately 55.9% of 
probes were hypomethylated in the schizophrenia group. Of those probes, 2 536 were in a 
promoter-associated region (surrounding a gene transcription start site) and 1 443 were both 
promoter-associated and located at a CpG island (Table 2). However, as the ages and PMI 
were significantly different between the controls and the schizophrenia patients, differential 
methylation analysis was performed again, this time adjusting for age and PMI. One sample 
from a patient with schizophrenia did not have age, sex, or PMI recorded, and hence they 
were excluded from the adjusted analysis.  
After adjusting for age and PMI, 4 641 probes were declared differentially methylated, with 
approximately 47.3% hypomethylated in the schizophrenia group.  The 4 641 probes 
corresponded to 2 929 unique genes (Supplementary Table 2).  Of those genes, 817 were 
promoter-associated and 599 were both promoter-associated and located at a CpG island. 
Furthermore, of the 599 genes both promoter-associated and located at a CpG island, 491 
were in common with the unadjusted results (Table 2). 
As expected altered DNA methylation mostly occurred in the CpG islands (29% unadjusted, 
34% adjusted; Figure 1) The proportion of probes in a CpG island found differentially 
methylated in the adjusted results is significantly higher than the overall proportion of probes 
found in CpG islands on the array as a whole (overall 30.9%; p = 1.23x10-5). Furthermore, a 
high percentage of aberrant DNA methylation occurred in promoter-associated regions, 
(13.0% unadjusted, 18.2 % adjusted; Figure 1).  The proportion in the unadjusted results is 
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significantly smaller than the proportion of promoter regions found on the arrays as a whole 
(overall 20.2%; p = 7.1x10-4). 
The adjusted and unadjusted lists have many genes in common with previously published 
results. The largest gene list available is that of Nishioka et al.(37) who published a list of 
589 unique genes associated with probes significantly differentially methylated between 
people with first episode schizophrenia and controls. Of the 589 genes found differentially 
methylated in the peripheral blood samples 99 overlap with the adjusted list.  Seven of the 
589 genes found by Nishioka et al. (11) were found by Reinius et al. (38) to be differentially 
methylated between leukocyte subtypes which would also explain differences in the two lists. 
A gene list was generated based on genes previously found associated with schizophrenia 
from genetic and or DNA methylation studies (11, 12, 19, 37).  This gene lists includes 
DRD2, NOS1, AKT1, HTR2A, SOX10, FOXP2, DTNBP1, NRG1, PPP3CC, BDNF, 
ZNF804A, NRGN, DRD4, MGST1, COMTD1 and GABRB2.  Genes identified as 
differentially methylated after adjustment include NOS1, AKT1, DNMT1, SOX10, DTNBP1 
and PPP3CC whose distributions can be seen in Figure 3.   
Cluster Analysis 
Clustering of the unadjusted beta values revealed three distinct groups, two containing mostly 
those with schizophrenia (78% and 100% respectively), whilst the other group contained a 
mixture of the two sample types (Table 3). 
Clustering of the age and autolysis adjusted beta values revealed two distinct groups, one 
containing mainly schizophrenia patients (88%), the other containing mainly controls (73%) 
(Table 3).  Cluster one had significantly more patients with schizophrenia compared to 
controls (χ2  = 14.1; df = 1; p = 1.74 x 10-4). The multi-dimensional scaling plots on both the 
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adjusted M and beta (Figure 2) further reinforce the distinction between schizophrenia 
patients and controls. 
Interpreting the results from these three analyses in conjunction, we can be conservatively 
confident that at least 12 out of the 24 patients are clearly distinguishable from controls.   
Differential methylation between schizophrenia groups 
The results of the clustering indicate that the methylation profiles in those with schizophrenia 
are a heterogeneous group. There were some profiles that were consistently deemed distinct 
from the controls, while there were others that were not found to be significantly dissimilar. 
Twelve samples in particular tended to exhibit the former trait.  When comparing these two 
potential subgroups of those with schizophrenia we can see that the two subgroups exhibit no 
obvious difference in characteristics (Table 4). Thus there is potential for methylation arrays 
to be used to detect differences within these two potential subgroups. 
Differential methylation analysis between the two schizophrenia sub-groups indicated that 
there were 73 222 probes that were differentially methylated (Table 5). Of those probes 6 681 
were promoter-associated and 2 006 were both promoter-associated and located at a CpG 
island. After adjusting for age and PM1, 56 001 probes were found to be differentially 
methylated (Supplementary Table 3), 4 779 being promoter-associated and 1 238 both 
promoter-associated and located at a CpG island. The abundance of differentially methylated 
probes suggests significant groupings within the schizophrenia methylation profile. By 
contrast, a history of completed suicide or presence of another psychiatric disorder revealed 
no significant differences in methylation. 
  
12 
 
Discussion 
Differential DNA methylation in schizophrenia has been reported in several studies to date, 
although most of these studies involve the use of non-functional tissues such as blood.  In this 
study we analysed DNA methylation status in brain tissue, the primary tissue of pathology in 
schizophrenia, employing a genome wide methylation array with very extensive coverage of 
the potential methylation sites in the human genome.  After adjusting for age and PMI 4 641 
probes corresponding to 2 929 unique genes were found to be differentially methylated.  
When we compared the differentially methylated gene list to past studies using peripheral 
leukocyte samples we found a high concordance rate particularly for genes previously found 
to be associated with schizophrenia.  Of the 589 genes Nishioka et al. found to be 
differentially methylated in peripheral blood cells from patients with schizophrenia we were 
able to replicate 99 of these in brain tissue (11).  This shows promise for the use of non-
invasive tissue such as blood or saliva to be used as a future diagnostic indicator of 
schizophrenia.  We are aware of only one other study that used the 450 Illumina array in 
schizophrenia, although peripheral leukocytes were analysed rather than brain tissue (19).  
That study identified 10 747 differential DNA methylation sites in medication free subjects 
(19).  One of the genes they identified was RAI1 which has altered DNA methylation in the 
present study as well as an earlier schizophrenia study using brain tissue (18).  Other genes 
found to be differentially methylated in both the leukocyte study and the present brain tissue 
study includes HDAC4, GFRA2 and GDNF.  The leukocyte study did not replicate COMTD1 
and HTR1A that were found to be differentially validated from a previous study in peripheral 
tissue (11, 19).  However, we report that these genes are differentially methylated in brain.  
Although we were able to validate many of the previously identified CpG sites, experimental 
validation using an alternative method such as pyrosequencing would also confirm our 
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results.  Functional significance of genes found to be differentially methylated should also be 
tested by gene expression.   
Unsupervised clustering of the top 3 000 most variable probes revealed two distinct groups 
after adjusting for age and PMI.  Cluster one was composed of 88% patients with 
schizophrenia and 12% controls while cluster two was composed of 27% patients with 
schizophrenia and 73% controls.  To our knowledge this is the first report of DNA 
methylation profiling that is able to significantly differentiate between those with 
schizophrenia and control subjects.  Although Nishioka et al. (11) was able to identify site-
specific DNA methylation changes in patients with schizophrenia they were unable to 
discriminate between controls and schizophrenia patients using unsupervised clustering (11).  
DNA methylation patterns differ in brain cells compared to peripheral tissues such as blood 
(20) and this may explain the lack of separation reported by Nishioka et al. (11).  Although 
some genes may have the same epigenetic profiles in peripheral and brain tissue a more 
comprehensive list of tissue specific genes may be required to differentiate controls from 
those with schizophrenia.  Another reason may be the analysis of fewer CpG sites (only 27 
000 compared to 450 000) in the previous study.  This is potentially important as a DNA 
methylation signature across the whole genome is required to identify the most important 
differentially methylated probes.  The results of our clustering analysis will need to be 
confirmed in an independent brain tissue cohort.   
Clustering analysis also revealed two subgroups within schizophrenia. It is possible that these 
two subgroups have specific symptomatology that warrants further investigation in a sample 
set with a comprehensive clinical history.  After adjusting for age and PMI DTNBP1, COMT 
and DRD2 were found to be differentially methylated between the two schizophrenia 
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subgroups.  Interestingly these are genes we have previously found to be associated with 
schizophrenia (39-42).   
A recent study has found significant DNA methylation changes in the early stages of 
development and suggest that aberrant DNA methylation during the transition from the fetal 
to the postnatal period of development could be critical for the pathogenesis of schizophrenia 
(43).  Genes that are differentially methylated from fetal to neonatal life stage include DRD2, 
NOS1, SOX10 and DNMT1 all of which have previously been found to be associated with 
schizophrenia.  We also found DNMT1, NOS1 and SOX10 to be differentially methylated in 
brain tissue from patients with schizophrenia.  However, after adjusting for age and autolysis 
DRD2 was not differentially methylated.   
The main limitation of our study was that patients were not free of antipsychotic medication 
and antipsychotic medication has been shown to influence DNA methylation.  A recent study 
reported that antipsychotic haloperidol was uniquely associated with higher global DNA 
methylation in patients with schizophrenia but other antipsychotic drugs were not associated 
with changes in methylation (25).  A further study observed antipsychotics may have anti-
inflammatory effects (44).  However as patients with chronic schizophrenia are almost certain 
to be treated with anti-psychotic medications future studies may only be able to adjust for 
antipsychotic medications in their analyses rather than eliminate these samples entirely.  Our 
samples were obtained from a brain bank and had limited medication history collected.  
Although controls did not have schizophrenia they were not screened for other psychiatric 
conditions such as depression.  Antipsychotic medication use was not screened for amongst 
the control subjects as these medications are not commonly used other than to treat psychosis.  
Another limitation is cell type heterogeneity in the frontal cortex brain tissue used in our 
analysis.  Our study did not account for differences in cell type seen in the frontal cortex and 
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a previous study has shown that the two major cell types, neurons and glia have different 
DNA methylation signatures (45).  Statistical methods that estimate brain cell types in gene 
expression studies (46) and more recently in DNA methylation studies (47) could be used in 
future brain DNA methylation studies.   
Our data indicate that studies of epigenetic changes in schizophrenia hold promise for the 
future development of diagnostic and prognostic biomarkers for schizophrenia as well as 
therapeutic options that target causative epigenetic alterations.  The key is to identify aberrant 
DNA methylation profiles in a functional tissue and determine if the results can be translated 
back into a diagnostically feasible tissue such as blood or saliva.  Identifying when DNA 
methylation changes occur is also important in understanding the origins of schizophrenia.  
During the critical period of development between pregnancy and birth altered DNA 
methylation occurs (43).  If gene-environmental factors can be identified that affect DNA 
methylation status, then the incidence of schizophrenia could possibly be reduced by 
targeting the environmental triggers.  To put together all the pieces of the schizophrenia 
puzzle gene-environment interactions need to be identified as well as how they influence 
epigenetics.  Over the years there have been numerous studies on the effects of SNPs on 
mRNA expression in schizophrenia but very few showing how SNPs affect gene expression 
through DNA methylation.  Investigating the involvement of SNPs and their interaction with 
the environment as well as their influence on epigenetics will benefit our understanding of the 
pathophysiology of schizophrenia.  The identification of enzymes that are capable of 
mediating DNA demethylation in mammalian cells as targets for therapeutic intervention is 
an exciting prospect that may hold the key to reversing this debilitating psychiatric illness 
(48).   
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Supplemental data include three tables and is available at Translational Psychiatry’s website.   
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Figure 1: Probes relation to CpG Island and probes regulatory feature group (A-B) Number 
of probes found in CpG islands, shelves (north and south) and shores (north and south) 
including those with no CpG island information (unknown), both (A) unadjusted and (B) 
adjusted for age and post-mortem interval. (C-D) Number of probes found in regions gene 
associated, non-gene associated, promoter associated and unclassified both (C) unadjusted 
and (D) adjusted for age and post-mortem interval (excluding those with no regulatory 
feature group information n=13214 and n=3002, respectively). 
Figure 2: Multi-dimensional scaling plot of the adjusted M-values with RPMM cluster of 
adjusted beta values denoted by black (cluster 1) or grey (cluster2) (A).  
Multi-dimensional scaling plot of the adjusted beta values with RPMM cluster of adjusted 
beta values denoted by black (cluster 1) or grey (cluster2) (B).  
Figure 3: Boxplots of beta values for the control and schizophrenia groups for probes 
associated with genes of interest. The median beta value is denoted by the solid middle line 
(A) “cg27026005” is promoter associated (PA) and located on a CpG island, it is associated 
with AKT1 (B) “cg01749142” is PA and located on a shore, it is associated with AKT1. (C) 
“cg21273407” is located on a CpG island, it is associated with NOS1. (D) “cg23401624” is 
located on a CpG island and is PA, it is associated to DNMT1. (E) “cg06128182” is located 
on a CpG island and is PA, it is associated to DNMT1. (F) “cg06614002” is located on a 
shore and is associated with SOX10 
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Table 1: Demographic data for control and schizophrenia patients 
  Control Schizophrenia p-value 
n=24 n=231 
Age (mean) 71.3 51.6 <0.001 
sd 9.8 21.6   
PMI2 (mean) 14.1 23.8 <0.001 
sd 3.3 10.4   
Sex – Male  19 16 0.67 
(%) 79% 67% 
        
  1One patient did not have age, sex, or PMI recorded 
  2PMI is the time between death and brain tissue quick frozen 
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Table 2: Number of probes found differentially methylated between control and 
schizophrenia patients both unadjusted and adjusting for age and post-mortem interval (PMI). 
  Unadjusted Adjusted  Common1 
  Probes  Genes Probes  Genes   
All 19582 7832 4641 2929 2632 
Promoter-associated 2536 2084 844 817 677 
CpG Islands 5650 3336 1575 1291 1083 
Promoter-associated 
and Islands 1443 1349 572 599 491 
 1 Genes in common with un-adjusted results 
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Table 3: Characteristics of those in the RPMM clusters for both unadjusted and adjusted beta 
values 
    Unadjusted Adjusted 
Clusters   1 2 3 1 2 
n   9 5 34 17 30 
Schizophrenia n 7 5 12 15 8 
  % 78% 100% 35% 88% 27% 
Males n 7 2 26 10 25 
  % 78% 40% 76% 59% 83% 
Death by suicide n 3 0 2 2 3 
  % 33% 0% 6% 12% 10% 
Age mean 44.8 69.8 65 59.8 62.7 
std 19.6 5 18.2 19.3 19.4 
PMI1  mean 21.6 20.6 17.8 19.9 18.3 
  std 8.7 8.7 12.3 9.0 9.2 
1PMI is the time between death and brain tissue quick frozen 
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Table 4: Characteristics of those identified as being in schizophrenia sub groups based on 
clustering results 
Subgroups 1 2 
n 12 121 
Males n 7 9 
% 58% 82% 
Death by 
suicide n 3 2 
% 25% 17% 
Age mean 51.4 51.8 
std 20 24.1 
PMI mean 22 25.7 
std 10.2 10.8 
1one person in this group did not have sex, age or post-mortem interval 
recorded 
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Table 5: Number of probes found differentially methylated between schizophrenia subgroups 
  Unadjusted Adjusted  Common1 
  Probes Genes Probes Genes   
All 73222 14701 56001 12625 12501 
Promoter-associated 6681 3979 4779 2934 2851 
CpG Island 10628 4450 7598 3218 3106 
Promoter-associated 
and Island 2006 1546 1238 919 861 
    1Genes in common with un-adjusted results 
